SCHEMBL2067183

SCHEMBL2067183

NCCc1cc(Br)cnc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 6/20 0.37
HTR2A P28223 4/20 0.37
HTR2C P28335 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
RAD52 P43351 2/20 0.36
RECQL P46063 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
HTT P42858 1/20 0.36
GAPDH P04406 1/20 0.36
THRB P10828 1/20 0.36
APEX1 P27695 1/20 0.36
BLM P54132 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35
AGO2 Q9UKV8 1/20 0.35
HRH1 P35367 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067701 0.84 HTT (0.39) KMT2AHTT
SCHEMBL15923198 0.81 KMT2A (0.32) KMT2AMEN1HTTMAPT
SCHEMBL2068328 0.77 HRH1 (0.41) TAAR1HTR2AHTR2CKMT2AMEN1
SCHEMBL2066886 0.77 KMT2A (0.36) TAAR1HTR2AHTR2CKMT2AMEN1
SCHEMBL4541092 0.76 OPRK1 (0.39) KMT2AMEN1HTTMAPTMAPK1
SCHEMBL29054010 0.76 HTT (0.34) KMT2AHTT
SCHEMBL19759439 0.76 SMN1; SMN2 (0.35) KMT2AHTTKDM4EMAPTHSD17B10
SCHEMBL29009928 0.75 NPSR1 (0.42)
SCHEMBL2946177 0.74 HTT (0.38) TAAR1HTR2AKMT2ATDP1HTT
SCHEMBL26041676 0.74 HTT (0.33) KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 TAAR1 3825/4885HTR2A 2710/4885HTR2C 1885/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 TAAR1 3825/4885HTR2A 2710/4885HTR2C 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.